Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model (Q38245841)

31 August 2017

title

Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model (English)

1 reference

31 August 2017

1 reference

François-Clément Bidard

6

François-Clément Bidard

0 references

Magali Lacroix-Triki

2

Magali Lacroix-Triki

0 references

Olivier Mir

Olivier Mir

8

0 references

Olivier Trédan

1

Olivier Trédan

1 reference

31 August 2017

Magali Lacroix-Triki

2

1 reference

31 August 2017

Séverine Guiu

3

1 reference

31 August 2017

Marie-Ange Mouret-Reynier

4

1 reference

31 August 2017

Jérôme Barrière

5

1 reference

31 August 2017

Antoine-Laurent Braccini

7

1 reference

31 August 2017

Christian Villanueva

9

1 reference

31 August 2017

Philippe Barthélémy

10

1 reference

31 August 2017

publication date

5 September 2014

1 reference

31 August 2017

1 reference

31 August 2017

volume

10

1 reference

31 August 2017

issue

2

1 reference

31 August 2017

page(s)

189-198

1 reference

Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies.

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

Hypoxia signalling in cancer and approaches to enforce tumour regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

Tumor cell metabolism: cancer's Achilles' heel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

Openings between defective endothelial cells explain tumor vessel leakiness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

Tumor angiogenesis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

Angiogenesis in life, disease and medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

Drug resistance and the solid tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

Normalization of the vasculature for treatment of cancer and other diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

A role for VEGF as a negative regulator of pericyte function and vessel maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

Simultaneous measurement of RBC velocity, flux, hematocrit and shear rate in vascular networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

Pathology: cancer cells compress intratumour vessels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

Endoglin: An accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

Vascular endothelial growth factor expression in the basal subtype of breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

The association between vascular endothelial growth factor expression in invasive breast cancer and survival varies with intrinsic subtypes and use of adjuvant systemic therapy: results from the Nurses' Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

Vascular proliferation is increased in basal-like breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

Moesin expression is a marker of basal breast carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

Bevacizumab added to neoadjuvant chemotherapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab--initial experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-014-0334-9

Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse

21 January 2018

1 reference

12 December 2020

Acid pH in tumors and its potential for therapeutic exploitation

1 reference

12 December 2020

Bevacizumab improves the delivery and efficacy of paclitaxel

1 reference

12 December 2020

Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications

1 reference

12 December 2020

Interstitial hypertension in human breast and colorectal tumors

1 reference

12 December 2020

Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody

1 reference

12 December 2020

Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases.

1 reference

12 December 2020

Interstitial hypertension in carcinoma of uterine cervix in patients: possible correlation with tumor oxygenation and radiation response

1 reference

12 December 2020

Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer

1 reference

12 December 2020

Determinants of tumor blood flow: a review

1 reference

12 December 2020

Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma

1 reference

12 December 2020

First-line bevacizumab-containing therapy for triple-negative breast cancer: analysis of 585 patients treated in the ATHENA study

1 reference

12 December 2020

Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma

1 reference

12 December 2020

The prognostic value of angiogenesis by Chalkley counting in a confirmatory study design on 836 breast cancer patients

1 reference

12 December 2020

Interstitial fluid pressure in solid tumors following hyperthermia: possible correlation with therapeutic response

1 reference

12 December 2020

Neovascularization evaluated by CD105 correlates well with prognostic factors in breast cancers

1 reference

12 December 2020

Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis

1 reference

12 December 2020

RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic br

1 reference

12 December 2020

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial

1 reference

12 December 2020

10.1007/S11523-014-0334-9

Identifiers

DOI

1 reference

Dimensions Publication ID

31 August 2017

1023018580

0 references

1 reference